Kedrion Announces An Eight-Year Extension Of The Distribution Agreement With Kamada In The U.S. For Kedrab
Since 2018 Kedrion has had exclusive distribution rights in the US for KEDRAB®, a Human Rabies Immune Globulin (HRIG) developed in partnership with Kamada Ltd. New agreement becomes effective in January 2024